What PathomIQ does

PathomIQ (PATHOMIQ, Inc.) is a private, clinical-stage AI company founded in 2017 and headquartered in Cupertino, California, that develops AI-powered biomarker discovery and precision medicine tools for cancer diagnosis. The company's core technology is a proprietary Phenotype Atlas — a deep learning system trained on thousands of H&E-stained whole slide images from multiple tier-1 cancer centers — that produces interpretable predictions of treatment response, disease progression, and molecular alterations directly from routine pathology slides. PathomIQ has built five named AI tests across three oncology indications: PATHOMIQ_PRAD and PATHOMIQ_AS for prostate cancer (metastasis risk and active surveillance decisions), PATHOMIQ_BRCA and PATHOMIQ_TNBC for breast cancer (ER+ recurrence risk and triple-negative chemotherapy response), and PATHOMIQ_BLCA for non-muscle invasive bladder cancer (BCG failure and recurrence prediction).

PathomIQ generates revenue primarily through technology licensing and channel partnerships rather than direct sales. Its commercial strategy is anchored by an exclusive US licensing agreement with Myriad Genetics (signed February 2025) for PATHOMIQ_PRAD, which has been embedded into Myriad's Prolaris franchise and commercially launched as Prolaris + AI in May 2026. Global deployment beyond the US is enabled through a multi-year partnership with Neuberg Diagnostics (signed June 2023), which offers PathomIQ's AI biomarkers as Laboratory Developed Tests through its worldwide laboratory network. The company also operates a cloud-based decentralized platform that allows healthcare institutions to submit digitized slides for direct analysis.

The company serves oncologists, urologists, breast cancer specialists, and pathologists at academic medical centers, cancer centers, and hospital systems — with clinical validation partnerships at Cleveland Clinic, MD Anderson Cancer Center, Icahn School of Medicine at Mount Sinai, University of Miami, and the VA Healthcare System. Leadership combines academic credibility (former MD Anderson Vice Provost as CMO, MD Anderson pathologist as co-founder) with AI/ML research depth (Director of ML Research from Columbia and Cambridge; principal scientists from MSK and Harvard/MIT), and the company is currently in early commercial scaling with a small disclosed headcount of 1–10 employees.

Name

PathomIQ

Legal name

PATHOMIQ, Inc.

Website

https://pathomiq.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

PathomIQ is a private AI company that develops deep learning models on H&E pathology images to predict cancer treatment response and prognosis across prostate, breast, and bladder cancers, commercializing through an exclusive US license to Myriad Genetics (Prolaris + AI) and a global LDT partnership with Neuberg Diagnostics.

Ownership category

akta.pro rank

Product category

AI Digital Pathology / Precision Oncology Diagnostics

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Medical and Diagnostic Laboratories (62151)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Oncology Pathways & Precision Medicine Decision Support (HLACAGAH)

akta.pro secondary industry

Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers) (HLAAAMAI)

Keywords

• AI cancer diagnostics
• Precision medicine biomarkers
• Digital pathology AI
• Oncology prediction software
• Multiomics platform

Headquarters

HQ city

Cupertino

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Technology Licensing: PathomIQ licenses its AI technology platforms to established diagnostics companies. The exclusive licensing agreement with Myriad Genetics for PATHOMIQ_PRAD in the US represents a primary revenue stream through upfront payments, milestone payments, and ongoing royalties.
2. Lab Developed Tests (LDT): Partner laboratories deploy PathomIQ's AI-based prognostic and predictive biomarkers as Laboratory Developed Tests, with PathomIQ receiving compensation through the partnership arrangement with companies like Neuberg Diagnostics for worldwide deployment.
3. Cloud Platform Services: Cloud-based decentralized AI platform enabling easy global implementation and scalable logistics for analyzing digitized pathology slides. Revenue generated through per-test or subscription-based pricing for platform access.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

PathomIQ develops and commercializes AI-powered precision medicine tests that analyze digitized H&E-stained whole slide images to predict cancer treatment response, metastasis risk, and disease progression. Its proprietary Phenotype Atlas powers named products across prostate (PATHOMIQ_PRAD, PATHOMIQ_AS), breast (PATHOMIQ_BRCA, PATHOMIQ_TNBC), and bladder (PATHOMIQ_BLCA) cancers, delivered via technology licensing to diagnostics partners (Myriad Genetics, Neuberg Diagnostics) and direct cloud-based platform access to healthcare institutions.

Product overview

PathomIQ offers a unified AI platform (PATHOMIQ AI Platform) that delivers multiple diagnostic and prognostic tests across three cancer types: prostate (PATHOMIQ_PRAD, PATHOMIQ_AS), breast (PATHOMIQ_BRCA, PATHOMIQ_TNBC), and bladder (PATHOMIQ_BLCA). The platform is powered by a proprietary phenotype atlas that analyzes H&E-stained whole slide images to predict treatment response, outcomes, and biomarker discoveries. The products range from risk stratification tests (PATHOMIQ_PRAD for metastasis risk) to therapy response predictors (PATHOMIQ_TNBC for chemotherapy response, PATHOMIQ_AS for active surveillance decisions). The technology is cloud-based and decentralized for global implementation.

Differentiator

Problem solved

Functional benefit

Brands

• PATHOMIQ_PRAD: AI-based prostate cancer test analyzing digitized H&E radical prostatectomy whole slide images to assess risk of biochemical relapse and metastasis.
• PATHOMIQ_AS
• PATHOMIQ_BRCA
• PATHOMIQ_TNBC
• PATHOMIQ_BLCA

Products and services

• PATHOMIQ AI Platform Cloud-based, decentralized AI-driven multiomics platform powered by a proprietary Phenotype Atlas. Analyzes digitized H&E-stained whole slide images to predict cancer treatment response, outcomes, biomarker discovery, and precision cancer grading. Combines expert pathologist supervision with AI-learned morphological features trained on thousands of slides from multiple medical institutions, enabling rapid deployment to new use cases with minimal outcome data. Targets academic medical centers, cancer centers, hospital systems, and diagnostics partners.
• PATHOMIQ_PRAD AI-based prognostic test for prostate cancer that analyzes digitized H&E radical prostatectomy whole slide images to assess risk of biochemical relapse and metastasis. Stratifies intermediate-risk patients into high and low risk categories, identifies high-risk patients who could benefit from early intervention, and predicts response to anti-androgen apalutamide treatment. Validated in a 1,294-patient study and shown to outperform currently used markers in both Caucasian and African American cohorts.
• PATHOMIQ_AS AI-based decision support model for personalizing management of patients on active surveillance for low- and intermediate-risk prostate cancer. Uses a multi-modal approach combining histopathology images, PSA data, and clinical data to predict disease progression, grade reclassification, and adverse pathology with individualized time-based risk estimates.
• PATHOMIQ_BRCA Cross-modality AI test that translates genomic biomarkers into H&E-based predictors of distant metastasis in early-stage ER+ breast cancer. Provides outcome stratification beyond Oncotype DX and identifies high-risk patients within both endocrine therapy and combination therapy groups, enabling more personalized treatment selection.
• PATHOMIQ_TNBC Deep learning AI model that predicts the likelihood of triple-negative breast cancer patients responding to neoadjuvant chemotherapy directly from routine H&E-stained biopsy images. Identifies patients likely to achieve pathological complete response, with demonstrated AUC 0.75, PPV 73.7%, and NPV 76.2% in validation studies.
• PATHOMIQ_BLCA Histopathology-driven AI biomarker that predicts progression, high-grade recurrence, and early BCG failure in non-muscle invasive bladder cancer (NMIBC) directly from routine H&E whole-slide images. Performance is enhanced when combined with tumor focality, and the model is independently associated with progression-free and high-grade recurrence-free survival in NMIBC patients.

Quantifiable outcome

• PATHOMIQ_TNBC achieves AUC 0.75, PPV 73.7%, NPV 76.2% in predicting neoadjuvant chemotherapy response in TNBC patients
• +3 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature9 records

Partnerships

Four partnerships are on record, tiered core and major.

• Myriad GeneticscoreTechnology or Integration · 24 February 2025Strategic collaboration where Myriad Genetics exclusively licenses PATHOMIQ_PRAD, PathomIQ's AI technology platform for prostate cancer, in the United States. Myriad integrated the AI technology into their Prolaris test, launching Prolaris + AI as the first prostate cancer biomarker test combining clinical-pathological features, molecular scores, and AI-powered digital pathology. The partnership was announced February 24, 2025 and represents a flagship commercial relationship.
• Neuberg DiagnosticsmajorChannel Partner/ Reseller/ Distributor · 6 June 2023Multi-year partnership to accelerate clinical deployment of PathomIQ's AI-based prognostic and predictive biomarkers as Laboratory Developed Tests (LDT) available in Neuberg Diagnostic's laboratories worldwide. This partnership expands global reach beyond the US market through Neuberg's established diagnostic laboratory network across multiple countries.
• Cleveland Clinic Glickman Urological & Kidney InstitutemajorStrategic or Co-development PartnerClinical validation partner and advisor relationship with Dr. Eric A. Klein, Chair of the Glickman Urological & Kidney Institute. Dr. Klein provides expertise in urologic oncology and has endorsed PathomIQ's technology for prostate cancer risk assessment.
• MD Anderson Cancer CentermajorStrategic or Co-development PartnerMultiple collaborative relationships with MD Anderson departments including Pathology (Dr. Savitri Krishnamurthy) and Breast Medical Oncology (Dr. Debasish Tripathy). Former Vice Provost of Multidisciplinary Clinical Research at MD Anderson serves on the leadership team, indicating deep institutional ties for clinical validation and co-development.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Paige.AI: Paige builds AI applications for digital pathology with FDA-authorized products for prostate and breast cancer detection. It directly competes in H&E-based AI cancer diagnostics and prognostic biomarker development.
• PathAI: PathAI develops AI-powered pathology tools for cancer diagnosis and biomarker discovery using H&E whole slide images. It is the closest direct peer to PathomIQ in image-based AI biomarkers and treatment response prediction across multiple tumor types.
• Ibex Medical Analytics: Ibex offers an AI-powered cancer diagnostics platform deployed in clinical pathology workflows for breast, prostate, and GI cancers. Its clinical-grade H&E AI products overlap directly with PathomIQ's prostate and breast AI biomarker offerings.
• Owkin: Owkin applies AI to pathology images and multimodal clinical data to predict treatment response and enable precision oncology research and diagnostics. Comparable to PathomIQ's image-based prognostic and predictive biomarker platform.
• Proscia: Proscia is a digital pathology platform with AI applications for cancer diagnosis, biomarker discovery, and research. It competes with PathomIQ in enabling H&E-based AI analytics for life sciences and clinical pathology use cases.
• Nucleai: Nucleai applies AI to spatial biology and H&E tissue images for biomarker discovery and treatment response prediction in oncology. Directly comparable to PathomIQ's spatial, morphology-based AI biomarker approach.

Broad incumbents

• Tempus Labs: Tempus is a broad AI-enabled precision medicine platform combining multiomic data, pathology imaging, and clinical records for oncology. It overlaps with PathomIQ's AI-driven precision oncology thesis but operates at much larger scale and across modalities beyond H&E.
• Exact Sciences: Exact Sciences' Oncotype DX is the established genomic test that PATHOMIQ_BRCA is positioned to outperform in early-stage ER+ breast cancer. They are a broad incumbent in cancer diagnostics competing for the same clinical decisions in breast cancer risk stratification.
• Foundation Medicine: Foundation Medicine provides comprehensive genomic profiling for solid tumors and hematologic malignancies as a reference laboratory service. It is a broad incumbent in cancer molecular diagnostics that competes with AI-imaging approaches for guiding oncology treatment selection.

Emerging players

• 4D Path: 4D Path is a smaller AI digital pathology company building predictive biomarkers from H&E images. Comparable emerging competitor focused on treatment response prediction from routine pathology slides.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/pathomiq

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PathomIQ